SUCCESSFUL DIGITAL INTERVENTIONS IN RECENT CLINICAL TRIALS

Mahesh possesses 33+ years of global experience in the pharmaceutical and biotechnology industries, encompassing drug discovery and development, contract research, and manufacturing organizations. He possesses deep expertise in various key operational areas, including clinical and commercial operations, quality assurance, regulatory compliance, process development, project management, operational excellence, and capital projects. Before joining Veeda as Group CEO, Mahesh held senior leadership positions at notable companies such as Syngene International (part of the Biocon Group), Sanofi, and Biological E Limited. He also spent over 20 years in the United States, where he completed his PhD and worked with multinational pharmaceutical giants like Amgen and Monsanto. Mahesh earned his doctorate in Medicinal Chemistry from the University of Utah.

- Dr. Mahesh Bhalgat,

In an exclusive interview with Mandvi Singh, Managing Editor, Siliconindia, Dr. Mahesh Bhalgat, Group CEO & Managing Director, Veeda Lifesciences, shared his insights on 'Successful Digital Interventions in Recent Clinical Trials'.

In recent years, the integration of digital technologies has revolutionized the landscape of clinical trials. These advancements have not only streamlined the process but also enhanced the accuracy, inclusivity, and overall efficiency of trials. The use of technology-oriented solutions that aim to improve health include a wide range of tools, including mobile health applications, telemedicine, portable devices, and clinically integrated platforms that take advantage of electronic health files. There have been some very critical and most successful digital interventions in recent clinical trials that have significantly impacted and boosted the potential for future research.

The use of technology and digital tools is one of the most significant advancements in digital clinical trials are the use of wearable technologies and remote sensors. These devices have transformed data collection by providing continuous, real-time monitoring of participants' health metrics that measure a range of parameters, including heart rate, respiratory rate, and physical activity levels. The use of this technology enables researchers to gather comprehensive data without requiring participants to visit clinical sites, thus increasing convenience and participation rates. In May 2024, the FDA approved the use of the Apple Watch’s as a heart monitoring tool in a cardiovascular study. This approval allows researchers to use the Apple Watch to detect arrhythmias and monitor participants’ AFib burden, providing a noninvasive way to evaluate the effectiveness of cardiac ablation devices. This landmark decision allowed historical heartbeat data to be used as a secondary endpoint in studies.